Huang, Wei-ChunWei-ChunHuangSONG-CHOU HSIEHYEN-WEN WUHsieh, Tsu-YiTsu-YiHsiehWu, Yih-JerYih-JerWuKO-JEN LICharng, Min-JiMin-JiCharngChen, Wei-ShengWei-ShengChenSung, Shih-HsienShih-HsienSungTsao, Yen-PoYen-PoTsaoHo, Wan-JingWan-JingHoLai, Chien-ChihChien-ChihLaiCheng, Chin-ChangChin-ChangChengTsai, Hung-ChengHung-ChengTsaiHsu, Chih-HsinChih-HsinHsuCHENG-HSUN LUChiu, Yu-WeiYu-WeiChiuShen, Chieh-YuChieh-YuShenWu, Chun-HsienChun-HsienWuLiu, Feng-ChengFeng-ChengLiuYEN-HUNG LINYeh, Fu-ChiangFu-ChiangYehLiu, Wei-ShinWei-ShinLiuLee, Hui-TingHui-TingLeeWu, Shu-HaoShu-HaoWuChang, Chi-ChingChi-ChingChangChu, Chun-YuanChun-YuanChuHou, Charles Jia-YinCharles Jia-YinHouTsai, Chang-YouhChang-YouhTsai2023-09-052023-09-052023-031011-6842https://scholars.lib.ntu.edu.tw/handle/123456789/635054Pulmonary arterial hypertension (PAH), defined as the presence of a mean pulmonary artery pressure > 20 mmHg, pulmonary artery wedge pressure ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 2 Wood units based on expert consensus, is characterized by a progressive and sustained increase in PVR, which may lead to right heart failure and death. PAH is a well-known complication of connective tissue diseases (CTDs), such as systemic sclerosis, systemic lupus erythematosus, Sjogren's syndrome, and other autoimmune conditions. In the past few years, tremendous progress in the understanding of PAH pathogenesis has been made, with various novel diagnostic and screening methods for the early detection of PAH proposed worldwide.enConnective tissue diseases; Pulmonary arterial hypertension; Sjogren’s syndrome; Systemic lupus erythematosus; Systemic sclerosis[SDGs]SDG3journal article10.6515/ACS.202303_39(2).20230117A369115492-s2.0-85149620835